Patents by Inventor Marcia MacDonald

Marcia MacDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for silencing apolipoprotein C-III expression
    Patent number: 9428751
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 30, 2016
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Marcia MacDonald, Amy C. H. Lee, Ian MacLachlan
  • Methods For Identifying Analgesic Agents
    Publication number: 20160166541
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: January 27, 2016
    Publication date: June 16, 2016
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Methods for identifying analgesic agents
    Patent number: 9278088
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION
    Publication number: 20150315584
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Application
    Filed: April 1, 2015
    Publication date: November 5, 2015
    Applicant: PROTIVA BIOTHERAPEUTICS, INC.
    Inventors: Marcia MacDonald, Amy C.H. Lee, lan MacLachlan
  • Compositions and methods for silencing apolipoprotein C-III expression
    Patent number: 9023820
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: May 5, 2015
    Assignee: Protiva Biotherapeutics, Inc.
    Inventors: Marcia MacDonald, Amy C. H. Lee, Ian MacLachlan
  • Methods for Identifying Analgesic Agents
    Publication number: 20130210884
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 15, 2013
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION
    Publication number: 20120184595
    Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).
    Type: Application
    Filed: January 26, 2010
    Publication date: July 19, 2012
    Applicant: Protive Biotherapeutics, Inc.
    Inventors: Marcia MacDonald, Amy C.H. Lee, Ian MacLachlan
  • Methods for identifying analgesic agents
    Publication number: 20070212685
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Application
    Filed: February 19, 2003
    Publication date: September 13, 2007
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Goldberg
  • Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
    Publication number: 20070166711
    Abstract: Polynucleotide and polypeptide sequences for HFE2A, as well as mutations associated with juvenile hemochromatosis, and methods of utilizing these for the screening and identification of agents for the treatment of diseases of iron metabolism, including small organic compounds, are disclosed along with methods of treating and/or ameliorating diseases of iron metabolism, especially in human patients are disclosed. Diagnostic compounds, kits and methods using HFE2A are also described.
    Type: Application
    Filed: April 8, 2004
    Publication date: July 19, 2007
    Inventors: Mark Samuels, Erwin Ludwig, Marcia MacDonald, Patrick Franchini, Yigal Goldberg, Rajender Kamboj, George Papanikolaou
  • Hsan II related gene and expression products and uses thereof
    Publication number: 20060166207
    Abstract: Methods of utilizing a gene related to pain perception, herein dubbed HSN2, or its encoded protein, dubbed herein “sensorin,” for the screening and identification of agents for the treatment of pain, neuropathy and related disorders, especially small organic compounds, as well as methods of using these compounds to treat or otherwise ameliorate pain, neuropathy and related disorders in human patients. Novel polypeptides and polynucleotides, along with their nucleotide and amino acid sequences, are also disclosed.
    Type: Application
    Filed: November 12, 2003
    Publication date: July 27, 2006
    Inventors: Ronald Lafreniere, Marie-Pierre Dube, Marcia MacDonald, Mark Samuels